Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSD
Dates
study started
completion around
Principal Investigator
by Royya Modir, MD (ucsd)

Description

Summary

SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke.

Official Title

Strategy for Improving Stroke Treatment Response (SISTER) Trial

Details

Keywords

Ischemic Stroke, Stroke

Eligibility

Locations

  • UCSD Health La Jolla accepting new patients
    La Jolla California 92093 United States
  • UCSD Medical Center- Hillcrest Hospital accepting new patients
    San Diego California 92103 United States
  • Kaiser Permanente Los Angeles accepting new patients
    Los Angeles California 90027 United States
  • Sutter Medical Center withdrawn
    Sacramento California 95816 United States

Lead Scientist at University of California Health

  • Royya Modir, MD (ucsd)
    Associate Clinical Professor, Neurosciences, Vc-health Sciences-schools

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Translational Sciences, Inc.
ID
NCT05948566
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 300 study participants
Last Updated